Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.
Redenlab, a leading provider of innovative solutions in the field of pediatric and neurodevelopment communication, proudly announces that Professor Angela...
MEDIA RELEASERedenlab, a leading techbio company, proudly announces its recent feature on the highly acclaimed Huberman Podcast. The podcast episode...
